A precision therapy against cancers driven by KIT/PDGFRA mutations.

doi:10.1126/scitranslmed.aao1690

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Science translational medicine - 1 Nov 2017

Evans Erica K, Gardino Alexandra K, Kim Joseph L, Hodous Brian L, Shutes Adam, Davis Alison, Zhu Xing Julia, Schmidt-Kittler Oleg, Wilson Doug, Wilson Kevin, DiPietro Lucian, Zhang Yulian, Brooijmans Natasja, LaBranche Timothy P, Wozniak Agnieszka, Gebreyohannes Yemarshet K, Schöffski Patrick, Heinrich Michael C, DeAngelo Daniel J, Miller Stephen, Wolf Beni, Kohl Nancy, Guzi Timothy, Lydon Nicholas, Boral Andy, Lengauer Christoph

Abstract excerpt

Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Phosphorylation

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Open in PubMed

Identifiers

PMID: 29093181
DOI: 10.1126/scitranslmed.aao1690

Genes

KIT
PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A precision therapy against cancers driven by KIT/PDGFRA mutations.PMID 29093181Read ↗

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsSemantic proximity Read ↗

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.Semantic proximity Read ↗

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Semantic proximity Read ↗

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapiesSemantic proximity Read ↗

Targeting kinases with precisionSemantic proximity Read ↗

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST.Semantic proximity Read ↗

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.Semantic proximity Read ↗

Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.Semantic proximity Read ↗

Structure-based Scaffold Hopping Reveals Strategies to Overcome Oncogenic KIT and PDGFRA Mutation-Driven Drug-Resistance in GISTSemantic proximity Read ↗

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.